Leading healthcare IT analyst firm KLAS today released its 2020 Best in KLAS report. We are thrilled to announce that Bluesight for Controlled Substances received the honor of Category Leader in Drug Diversion Monitoring Solutions, earning a rating of 93.9 out of 100! The annual Best in KLAS report analyzes data from customers to provide accurate perspective on the products … Read More
KLAS report ranks Kit Check as the top performer with 93.9 rating for consistently delivering on product support, customer loyalty and quality of operations. WASHINGTON (January 31, 2020) — Kit Check™, the leader in automated and intelligent medication management solutions, today announced that its Bluesight™ for Controlled Substances diversion detection software has been named the Category Leader in Drug Diversion … Read More
WASHINGTON (October 3, 2019) — Kit Check, the leader in automated medication management solutions for hospitals, today announced that Vizient has extended its agreement with the company for its Bluesight for Controlled Substances (BCS) as well as Kit Check’s kit and tray processing system. Vizient is the nation’s leading health care performance improvement company serving more than 50% of the … Read More
Bluesight for Controlled Substances heralded in industry report, earns rating of 93.2 out of 100 WASHINGTON (August 20, 2019) — Kit CheckTM, the leader in automated medication management solutions for hospitals, today announced that its Bluesight for Controlled Substances (Bluesight) diversion prevention and controlled substance management solution has been recognized by leading analyst firm KLAS Research in its next-generation solution … Read More
Leading healthcare IT analyst firm KLAS today published its inaugural drug diversion monitoring solution report. We are thrilled to announce that Bluesight for Controlled Substances received top marks, earning a rating of 93.2* out of 100! KLAS’s “Drug Diversion Monitoring 2019, An Early Look at Emerging Vs. Established Technology” highlights hospitals and health systems’ need for drug diversion monitoring technology, … Read More
We are excited to announce the launch of our newest feature for the Bluesight for Controlled Substances (BCS) medication tracking and diversion risk detection platform: Investigation Portfolios. Designed to support ASHP investigation guidelines, the Investigations Portfolio dashboard allows hospital diversion teams to collaborate with each other throughout the process, ensuring thorough, unbiased investigations and adherence to established procedures. Many hospitals … Read More
Workflow collaboration tool helps hospitals locate possible diverters with accuracy Washington DC, June 25, 2019 — Kit Check, the leader in automated medication management solutions for hospitals, today announced the addition of a new feature to its Bluesight for Controlled Substances (BCS) medication tracking and diversion risk detection platform: Investigation Portfolios. Bluesight for Controlled Substances’ Investigation Portfolios tool was designed … Read More
Kit Check’s Clinical Solutions Specialist AJ Rivosecchi, Pharm.D., recently held a webinar to discuss what we call the diversion gap—the space between controlled substance dispense activity and documentation where inventory can go missing. Hosted by IHFDA, the webinar covers key findings from our 2018 Hospital Pharmacy Operations Report, especially as they relate to the opioid crisis. AJ discusses the need … Read More
Kit Check CEO Kevin MacDonald was recently interviewed by HISTalk and shared some thoughts on where the company started, where it is today, and where it’s headed. “We are approaching 500 hospitals now and growing very quickly. We are thrilled that we’re now tracking more than one new medication every second, but there’s still a lot of room to grow,” commented MacDonald.
In the day-to-day battle against drug diversion, most solutions look at the data to find statistical outliers. Often the focus is on clinicians who may be logging more transactions than their peers, or on medications that are administered in unusual amounts or that go missing. We can call this the “Who” and the “What.” But we really have to look … Read More
As the national conversation around opioid abuse continues to grow, hospitals grappling with citations, fines and the bad publicity that accompany these events are looking for solutions that can have both an immediate reduction in liability and set them up for long-term compliance and risk abatement.
As the opioid epidemic continues to make headlines, hospitals are facing increasing pressure to detect and prevent controlled substance diversion. In response, the American Society of Health-System Pharmacists (ASHP) released guidelines on developing a comprehensive diversion prevention program which builds upon similar publications by the CDC, DEA and The Joint Commission. Given the risks, hospitals should heed these guidelines to ensure they have the safeguards in place to avoid similar incidents that have plagued the headlines.